Ameritas Investment Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History

Ameritas Investment Partners’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$150K	Buy	8,346 +1,143	+16%	+$17.7K	﹤0.01%	1583
2026 Q1	$100K	Hold	7,203	–	–	﹤0.01%	1700
2025 Q4	$87K	Buy	7,203 +1,409	+24%	+$19.1K	﹤0.01%	1780
2025 Q3	$78.7K	Sell	5,794 -1,287	-18%	-$12.1K	﹤0.01%	1841
2025 Q2	$45.4K	Buy	+7,081	New	+$34.4K	﹤0.01%	2244
2024 Q2	–	Sell	-5,046	Closed	-$14.3K	–	3125
2024 Q1	$14.3K	Hold	5,046	–	–	﹤0.01%	2697
2023 Q4	$74.3K	Hold	5,046	–	–	﹤0.01%	1925
2023 Q3	$92.4K	Buy	5,046 +1,011	+25%	+$21.4K	﹤0.01%	1717
2023 Q2	$87K	Hold	4,035	–	–	﹤0.01%	1692
2023 Q1	$118K	Hold	4,035	–	–	﹤0.01%	1436
2022 Q4	$153K	Buy	4,035 +1,271	+46%	+$45.1K	0.01%	1315
2022 Q3	$77K	Buy	2,764 +2,020	+272%	+$50.4K	﹤0.01%	1678
2022 Q2	$14K	Hold	744	–	–	﹤0.01%	2708
2022 Q1	$10K	Buy	+744	New	+$16.8K	﹤0.01%	2788

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Ameritas Investment Partners's AMLX Position: Q2 2026 in Review

Ameritas Investment Partners increased its Amylyx Pharmaceuticals (AMLX) stake by 16% in Q2 2026, buying an estimated $17.7K and bringing the position to 8,346 shares worth $150K. The position accounts for ﹤0.01% of the portfolio, ranked #1583.

Ameritas Investment Partners first reported a position in AMLX in Q1 2022 and has held it in 14 quarters since. The position peaked at $153K in Q4 2022. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Ameritas Investment Partners held 8,346 shares of Amylyx Pharmaceuticals worth $150K as of Q2 2026.
Ameritas Investment Partners bought 1,143 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $17.7K.
Amylyx Pharmaceuticals made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #1583 holding.
Ameritas Investment Partners first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 14 quarters since.
Ameritas Investment Partners's Amylyx Pharmaceuticals position peaked at $153K in Q4 2022.
206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.